Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Medicus Pharma Ltd. - Common Stock (NQ:MDCX)

1.625 +0.095 (+6.21%)
Streaming Delayed Price Updated: 2:44 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Medicus Pharma Ltd. - Common Stock

< Previous 1 2 Next >
News headline image
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
From Medicus Pharma Ltd
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement
Via ACCESS Newswire
Disrupting a $6 Billion Skin Cancer Market: The Small-Cap Biotech (MDCX) Advancing a Non-Surgical Patch
Via AB Newswire
News headline image
Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Explore Novel Treatment Innovations that may Revolutionize Treatments for Prostate and Skin Cancers
From Medicus Pharma Ltd.
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Announces Filing of FDA Commissioner’s National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
SKNJCT-003 Doxorubicin containing Microneedle Array (D-MNA) clinical development program to non-invasively treat BCC aligns with national priorities of public health impact, unmet medical need, access,... 
From Medicus Pharma
Via GlobeNewswire
News headline image
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Receives Full United Kingdom Regulatory and Ethical Approvals To Expand Phase 2 Clinical Study (SKNJCT-003) To Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Via ACCESS Newswire
Medicus Pharma Ltd. (NASDAQ: MDCX) and the Patch That Could End Repetitive Cancer Surgeries
Via AB Newswire
Emerging Biotech Stars Poised for Multi-Billion-Dollar Breakthroughs (MDCX, ACTU, LTRN, TNXP)
Via AB Newswire
News headline image
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for Skinject(TM) in Patients with Gorlin Syndrome
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. Announces Collaboration with the Gorlin Syndrome Alliance to Pursue Compassionate Use Pathway for SKINJECT™ in Patients with Gorlin Syndrome
Gorlin Syndrome, also known as Nevoid Basal Cell Carcinoma Syndrome, is a rare inherited genetic disorder affecting 1 in 31,000 people worldwide that can develop 500-1000 Basal Cell Carcinoma (BCC)... 
From Medicus Pharma
Via GlobeNewswire
4 Clinical-Stage Biotechs to Watch as the Sector Rebounds (MDCX, AUPH, LEXX, EDSA)
Via AB Newswire
News headline image
Medicus Pharma Ltd. Announces First Patient Treated in United Arab Emirates (UAE) Sknjct-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Via ACCESS Newswire
4 Diagnostic Stocks Targeting 25%+ Annual Growth in a $20B Market (MDCX, ILMN, EXAS, GH)
Via AB Newswire
News headline image
Three Biotech Companies Redefining Value Creation Through Dual Strategies
Via ACCESS Newswire
News headline image
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
Via ACCESS Newswire
Medicus Pharma (Nasdaq: MDCX) Nears Surgery-Free Breakthrough in Oncology
Via AB Newswire
News headline image
Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE
Via ACCESS Newswire
Medicus Pharma (Nasdaq: MDCX) Bringing Scar-Free, Outpatient Treatment to an $8 Billion Cancer Market
Via AB Newswire
News headline image
Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration (FDA) Type C Meeting Supporting the Development of Skinject
Via ACCESS Newswire
News headline image
Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
Biotech Stocks Positioned to Transform Treatment With Next-Gen Therapeutics (MDCX, PRTC, RANI, INO)
Via AB Newswire
News headline image
Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)
Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma... 
Via Newsfile
News headline image
Medicus Pharma Ltd. To Present at Brookline Capital Markets
Via ACCESS Newswire
News headline image
4 Biotech Stocks at the Cutting Edge of Drug Delivery (MDCX, RNA, NBTX, ARWR)
Comtex News Network, Inc. is a content specialist offering actionable news distribution, global syndication, and traffic for your content 
Via News Direct
News headline image
Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing
Via ACCESS Newswire
4 Biotech Stocks at the Cutting Edge of Drug Delivery (MDCX, RNA, NBTX, ARWR)
Via AB Newswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.